Hedgehog signaling pathway: A novel target for cancer therapy: Vismodegib, a promising therapeutic option in treatment of basal cell carcinomas

Indian Journal of Pharmacology

Volumn 46, Issue 1, 2014, Pages 3-12

  Abidi, Afroz ^a  

^a SUBHARTI MEDICAL COLLEGE   (India)

Author keywords

Basal cell carcinoma; Hedgehog signaling pathway; Vismodegib

Indexed keywords

LIGAND; PROTEIN PATCHED; SMOOTHENED PROTEIN; VISMODEGIB;

AGEUSIA; ALOPECIA; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; AUTOCRINE EFFECT; BASAL CELL CARCINOMA; CANCER FATIGUE; CANCER STEM CELL; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEDGEHOG SIGNALING PATHWAY; HUMAN; HYPOKALEMIA; HYPONATREMIA; IN VITRO STUDY; LIGAND BINDING; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIGENE FAMILY; MUSCLE SPASM; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; UREMIA; VOMITING;

BASAL CELL CARCINOMA; HEDGEHOG SIGNALING PATHWAY; VISMODEGIB;

ANILIDES; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84893304089     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.124884     Document Type: Review

References (40)

1. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/ en/ [Last accessed on 2013 Mar 9].
2. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharm Sci 2009;30: 303-12.
3. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980;287: 795-801.
4. Lewis EB, Nüsslein-Volhard C, Wieschaus EF. The Nobel Prize in Physiology or Medicine 1995. Available from: http://www.nobelprize.org/nobel- prizes/ medicine/laureates/1995/ [Last accessed on 2013 Apr 22].
5. Østerlund T, Kogerman P. Hedgehog signalling: How to get from Smo to Ci and Gli. Trends Cell Biol 2006;16: 176-80.
6. Carpenter D, Stone DM, Brush J, Ryan A, Armanini M, Frantz G, et al. Characterization of two patched receptors for the vertebrate hedgehog protein family. Proc Natl Acad Sci U S A 1998;95: 13630-4.
7. Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates Hedgehog signaling at the primary cilium. Science 2007;317: 372-6.
8. Corcoran RB, Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci U S A 2006;103: 8408-13.
9. Harfe BD, Scherz PJ, Nissim S, Tian H, McMahon AP, Tabin CJ. Evidence for an expansion-based temporal Shh gradient in specifying vertebrate digit identities. Cell 2004;118: 517-28.
10. Keeler RF. Cyclopamine and related steroidal alkaloid teratogens: Their occurrence, structural relationship, and biologic effects. Lipids 1978;13: 708-15.
11. Paladini RD, Saleh J, Qian C, Xu GX, Rubin LL. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J Investig Dermatol 2005;125: 638-46.
12. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391: 90-2.
13. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5: 1026-33.
14. Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicke A, Scharwächter C, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152: 43-51.
15. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgård R, Undén AB. Deregulation of the hedgehog signalling pathway: A possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol 2006;208: 17-25.
16. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455: 406-10.
17. Hedge GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Mol Cancer Res 2008;6: 1928-36.
18. Visvader JE, Lindeman GJ. Cancer stem cell in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8: 755-68.
19. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16: 2743-8.
20. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, et al. An orally bioavailable small molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008;7: 2725-35.
21. Pink M, Proctor J, Briggs K, MacDougall J, Whitebread N, Tremblay MR, et al. Activity of IPI-926, a potent Hedgehog pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/- mice [abstract]. 2008; 99th AACR Annual Meeting Infinity Pharmaceuticals, Inc. Medullo Oral Presentation 1588, Cambridge, MA.
22. LoRusso PM, Rudin CM, Borad MJ, Vernillet L, Darbonne WC, Mackey H, et al. A first-in-human, first-in-class, phase 1 study of systemic Hedgehog pathway antagonist, GDC-0449, in patients with advanced solid tumors. J Clin Oncol 2008;26:3516.
23. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361: 1164-72.
24. Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 2009;5: 154-6.
25. Lauth M, Toftgard R. Non canonical activation of GLI transcription factors: Implications for targeted anti-cancer therapy. Cell Cycle 2007;6: 2458-63.
26. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Investig 2011;121: 148-60.
27. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, et al. The crosstalk of mTOR/ S6K1 and Hedgehog pathways. Cancer Cell 2012;21: 374-87.
28. Erivedg (vismodegib), prescribing information. South San Francisco, Calif.: Genentech; January 2012. Available from: http://www.gene.com/gene/ products/ information/erivedge/pdf/erivedge-prescribing.pdf. [Last accessed on 2013 Feb 22].
29. Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71: 435-44.
30. Lorusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, et al. Coadministration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: A pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol 2013;71: 193-202.
31. Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, et al. A single dose mass balance study of the hedgehog pathway inhibitor vismodegib (GDC- 0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011;39: 1460-7.
32. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17: 2502-11.
33. LoRusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17: 5774-82.
34. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17: 2512-20.
35. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366: 2180-8.
36. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366: 2171-9.
37. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18: 6509-18.
38. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clin Cancer Res 2013;19: 258-67.
39. FDA grants priority review for vismodegib for advanced skin cancer. Oncol Times 2011;33:5.
40. Cowey CL. Targeted Therapy for Advanced Basal-Cell carcinoma: Vismodeglib and Beyond. Dermatol Ther (Heidelb) 2013;3: 17-31.